Influence of inhaled iloprost on transpulmonary gradient of big endothelin in patients with pulmonary hypertension

Circulation

Volumn 107, Issue 11, 2003, Pages 1509-1513

  Wilkens, H ^a   Bauer, M ^a   Forestier, N ^a   Konig J ^a   Eichler, A ^a   Schneider, S ^a   Schafers H J ^a   Sybrecht, G W ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Endothelin; Hypertension, pulmonary; Prostaglandins

Indexed keywords

BIG ENDOTHELIN 1; ILOPROST; MITOGENIC AGENT; PROSTANOID; VASOACTIVE AGENT;

ADULT; AGED; ARTERIAL BLOOD; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG CLEARANCE; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RADIAL ARTERY; VENOUS BLOOD;

ADMINISTRATION, INHALATION; ADULT; AGED; ENDOTHELIN-1; ENDOTHELINS; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; ILOPROST; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PULMONARY CIRCULATION;

EID: 0037465729     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000056104.49686.4B     Document Type: Article

References (22)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med. 1997;336:111-117.
2. Barst RJ. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart. 1997;77:299-301.
3. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension: an uncontrolled trial. German PPH Study Group. Ann Intern Med. 2000;132:435-443.
4. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
5. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
6. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000;102:2434-2440.
7. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for PAH. N Engl J Med. 2002;346:896-903.
8. Dupuis J, Cernacek P, Tardif JC, et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J. 1998;135:614-620.
9. Pernow J, Hemsen A, Lundberg JM, et al. Potent vasoconstrictor effects and clearance of endothelin in the human forearm. Acta Physiologica Scandinavica. 1991;141:319-324.
10. D'Orleans Juste P, Lidbury PS, Telemaque S, et al. Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1. J Cardiovasc Pharmacol. 1991;17(suppl 7):S251-S255.
11. Langleben D, Barst RJ, Badesch D, et al. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension. Circulation. 1999;99:3266-3671.
12. Rich S. Executive Summary from the world symposium on primary pulmonary hypertension. Available at: http://www.who.int/ncd/cvd/ pph.htm. Accessed October 10, 2002.
13. Stangl K, Dschietzig T, Richter C, et al. Pulmonary release and coronary and peripheral consumption of big endothelin and endothelin-1 in severe heart failure: acute effects of vasodilator therapy. Circulation. 2000;102:1132-1138.
14. Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. 2002;105:1034-1036.
15. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464-469.
16. Yamamoto K, Ikeda U, Mito H, et al. Endothelin production in pulmonary circulation of patients with rnitral stenosis. Circulation. 1994;89:2093-2098.
17. Imokawa G, Kobayashi T, Miyagishi M, et al. The role of endothelin-1 in epidermal hyperpigmentation and signaling mechanisms of mitogenesis and melanogenesis. Pigment Cell Research. 1997;10:218-228.
18. Clement MG, Albertini M. Differential release of prostacyclin and nitric oxide evoked from pulmonary and systemic vascular beds of the pig by endothelin-1. Prostaglandins Leukot Essent Fatty Acids. 1996;55:279-285.
19. Oriji GK, Tate JE, Keiser HR. Endothelin-induced prostacyclin production in rat aortic rings is mediated by protein kinase C. Prostaglandins Leukot Essent Fatty Acids. 1996;55:309-313.
20. Wright HM, Malik KU. Prostacyclin formation elicited by endothelin-1 in rat aorta is mediated via phospholipase D activation and not phospholipase C or A2. Circ Res. 1996;79:271-276.
21. Chou SY, Dahhan A, Porush JG. Renal actions of endothelin: interaction with prostacyclin. Am J Physiol. 1990;259:F645-F652.
22. Prins BA, Hu RM, Nazario B, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem. 1994;269:11938-11944.